千金药业2025年业绩增长近25% 并购整合与新品上市成看点

Core Viewpoint - The company, Qianjin Pharmaceutical, achieved revenue growth in 2025 and completed the acquisition and integration of two subsidiaries, with plans to launch a new product, Dingkundan, in 2026 [1]. Financial Performance - In 2025, the company reported a revenue of 3.635 billion yuan, a year-on-year increase of 0.13%; net profit attributable to shareholders was 288 million yuan, up 24.74%. The growth was primarily driven by stable core industrial operations and the consolidation of acquired subsidiaries [2]. Project Advancement - In Q4 2025, the company acquired a 28.92% stake in Qianjin Xiangjiang Pharmaceutical for 623 million yuan and a 68% stake in Qianjin Xieli Pharmaceutical, completing the consolidation in October and November. Post-transaction, the holding in Xiangjiang Pharmaceutical increased to 79.92%, and Xieli Pharmaceutical became a wholly-owned subsidiary, expected to enhance collaboration and profitability in the chemical pharmaceutical sector [3]. Product Development Progress - During the performance briefing in November 2025, the company announced that Dingkundan is expected to be launched in 2026, which may enrich the product line and contribute additional revenue [4]. Strategic Advancement - According to the strategic plan for 2024-2031, the company aims to achieve revenue of 8 billion yuan by 2031. Digital transformation has been implemented in production and procurement, with over 50% automation in key processes, indicating a focus on efficiency improvement in the future [5]. Business Development Status - In 2025, three products were selected in the 11th batch of centralized procurement, entering a market worth tens of billions; the e-commerce channel is rapidly growing, which may continue to influence the business layout [6].